Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (April 2019)
22 slides from Genetic Technologies's investor presentation, Apr 3, 2019
Slide 1: Forward looking statements
Forwardlookingstatements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of
Slide 2: Who we are
Whoweare Research and Development leader in the genomics sector • Developing and commercialising a suite of genetic risk assessment • Progressive R&D and commercialisation partner to products mortality 20 years to prevent morbidity and across a range of diseases experience bringing • • • Universitie
Slide 3: Our vision
Our vision • To empower individuals to manage and reduce their risk of contracting cancer and other chronic diseases We continually strive to maintain our standing as a global leader in genomics by investing in our own research capabilities and by forming partnerships with world-class/expert organis
Slide 4: GTG corporate overview
gGenetic GTG corporate overview Technologies Genetic Technologies Limited Melbourne, Australia ·Technical and corporate support ·CLIA approved laboratory Genetic Technologies HK Ltd. Hong Kong ·Holding compa..n..y.. ., Hainan Aocheng Genetic Technologies Co Ltd Hainan, China ·Operations in China ·Di
Slide 5: Our genetic test predicts a woman's risk of developing breast cancer
Ourgenetictestpredictsawoman’srisk ofdevelopingbreastcancer BREVAGenplus® is a first-to-market, clinically validated genetic risk assessment for non-hereditary (sporadic) breast cancer Simple cheek swab that helps determine a woman’s risk of developing breast cancer First test of its kind to be clin
Slide 6: Precision medicine
Precisionmedicine 1 in eight women will get breast cancer in their lifetime Screening programs that test all women at the same intervals overscreening 7 women and underscreening 1 woman • • will be Our risk assessment test offers health policy regulators and clinicians the potential for more efficie
Slide 7: Early detection = better outcomes
Earlydetection =better 5 year survival rates dramatically outcomes improve when breast cancer is diagnosed before spreading to other parts of the body 8 https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
Slide 8: Early diagnosis = less expensive treatment
Early diagnosis =lessexpensive treatment Stage I $ 55,000 First year treatment costs for Stage II $103,000 breast cancer Stage III and IV $127,000 USD, study based on US patients, 2003-2010 9 https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0207993.t001
Slide 9: Targeted screening and prevention
Targetedscreening and prevention Screening More frequent mammograms or MRIs BREVAGenplus® enables the targeting of limited resources to women who are most likely to develop breast cancer. Medication Selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs) Lifestyle Weight loss, a
Slide 10: We are developing new genetic screening tests
Wearedeveloping new genetic screening tests 2Q 2019 3Q 2019 4Q 2019 2020 * Tests are developed and market launch is scheduled. 11
Slide 11: GTG's enhanced breast cancer test covers 95% of women
GTG’senhancedbreast covers95% ofwomen cancer test Only 5% of women with breast cancer have a pathogenic variant, such as BRCA • 85% of women have no family history of breast cancer 10% have a family history but no pathogenic variants, such as BRCA • 95% of women Our test covers 12 * Pathogenic varia
Slide 12: GTG has developed a world-first polygenic risk test for colon cancer
GTG hasdevelopedaworld-first polygenicrisktest for colon cancer Risk stratification enables precision screening and Easy-to-use test solves personalised prevention the compliance problem Clinically actionable results 5-year, 10-year and lifetime risk Informs screening and health monitoring for those
Slide 13: Collaboration with world-leading partners
Collaboration with world-leading partners
Slide 14: Collaboration is a key market advantage
Collaboration isakey market advantage The University of Melbourne • Australia’s peak research-intensive institution, ranked 32nd globally Our • collaboration with The University of Melbourne was awarded an NHMRC grant Research investigation to assess the improvement in breast cancer risk prediction
Slide 15: Research into clinical applications
Research into clinical applications GTG has an agreement in place with Memorial Sloan Kettering (MSK) and University of Cambridge • The research is led by Mark E. Robson, MD, Chief of Breast Medicine Service, Memorial Sloan Kettering MSK is the world’s oldest and largest cancer treatment and researc
Slide 16: Other key partnerships
Other key partnerships Ohio State University (Columbus, Ohio) •Research collaboration exploring polygenic risk as a means to more informed decision-making for women with BRCA mutations •Led by Amanda Toland, Director of Clinical Genetics and a leader in the field of breast cancer risk assessment Nur
Slide 17: Intellectual property is our advantage
Intellectual property isouradvantage GTG has a strong patent portfolio covering the breast cancer risk assessment test 5 Patents granted in China 5 Patents granted in the US • Patent Nos. 200680051710.0; 201310524782.4; 201310524916.2 and • Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering thr
Slide 18: Hainan Medical Pilot Zone
HainanMedical PilotZone GTG has established its Asian operations with the formation of Genetic Technologies HK and Hainan Aocheng Genetic Technologies • • Part of the Hainan Free Trade Zone Initiative Best-in-class medical care, physicians, treatments, technology and cutting-edge medical product dev
Slide 19: GTG's approach aligns with Healthy China 2030
GTG’sapproachalignswithHealthy China2030 Healthy China 2030 is the Chinese Central Government’s comprehensive healthcare policy for 1.5 billion people • • Disease prevention is a means of controlling costs Chinese government can enforce compliance with preventive healthcare protocols GTG tests can b
Slide 20: Next Steps in China
Next Stepsin China Develop collaborative relationships Deliver the benefits of genetic screening • • • • Clinical validation Regulatory approval Commercial channels • Go-to-market plan for additional genetic screening tests Engagement with key opinion leaders • • Collaboration organisations with Chi
Slide 21: Thank you
Thank you Paul Kasian Chairman and CEO paul.kasian@gtglabs.com www.gtgcorporate.com 23
Slide 22: Genetic Technologies - Thank you
Genetic _ Technologies Thank you Paul Kasian Chairman and CEO paul.kasian@gtglabs.com www.gtgcorporate.com
Genetic Technologies — Investor Presentation (April 2019) on 6ix